News

Pfizer's Turnaround Has Truly Started (Earnings Update)
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE stock is a Buy.
Pfizer (PFE) Reports Earnings Tomorrow: What To Expect
Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what to look for.
Pfizer beats in Q2 earnings, reaffirms 2025 outlook
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 billion in revenues. The company reported revenues of $14.7 billion, compared to Wall Street expectations of $13.5 billion, and earnings per share of $0.78, versus estimates of $0.58 per share.
Pfizer: Q2 Earnings Snapshot
The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 58 cents per share. The drugmaker posted revenue of $14.65 billion in the period, also topping Street forecasts.
Pfizer Inc. (PFE) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ETCompany ParticipantsAamir Malik - Corporate ParticipantAlbert Bourla
Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
Pfizer PFE reported second-quarter 2025 adjusted earnings per share of 78 cents, which comprehensively beat the Zacks Consensus Estimate of 58 cents per share. Earnings rose 30% year over year. Revenues came in at $14.
Pfizer Stock Pops on Q2 Beat-and-Raise
Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast
Pfizer lifts 2025 profit forecast after strong Q2 beats, shares rise
Pfizer (NYSE:PFE) raised its full-year earnings outlook on Tuesday after reporting second-quarter results that surpassed Wall Street expectations, driving its shares up more than 3% in premarket trading.
Pfizer (NYSE:PFE) Reports Upbeat Q2
Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, close to analysts’ estimates.
TipRanks on MSN12h
Pfizer’s Updated COVID-19 Vaccine Study: What Investors Need to Know
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Estimated Vaccine Effectiveness ...
This 7% Yielding Stock Just Raised Its Profit Forecast. Is It Time to Buy?
The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...
Should You Buy Pfizer Stock Ahead of Its Q2 Results?
In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the company generated $62 billion in revenue and sustained operational ...
Pfizer stock soars as earnings smash expectations, and company raises outlook
Pfizer's stock surges as the pharmaceutical company reports stronger-than-expected earnings, raised profit forecasts, and ...
TipRanks on MSN1d
Pfizer’s Xeljanz Study: A Closer Look at Safety in Juvenile Arthritis
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is currently conducting a post-marketing surveillance study ...
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.